Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The OCTOVA Trial is open to recruitment at its first site. This multi-centre, randomised, open-label phase II trial will compare the activity and toxicity of chemotherapy (weekly Paclitaxel) to a novel agent Olaparib, and also Olaparib to the combination of Olaparib and Cediranib in women with advanced ovarian cancer and a gene mutation (BRCA gene). Olaparib is expected to be as active but less toxic than chemotherapy. This will be the first time that the combination of Olaparib and Cediranib has been tested in women with multiply relapsed platinum resistant ovarian cancer and a BRCA mutation.

Similar stories

AVID-CC trial opens to recruitment!

OCTRU

The AVID-CC trial has received OCTRU Green Light approval and is now open to recruitment!

WHiTE Four trial results published

Hip Main OCTRU Orthopaedics and trauma Research Trauma

The results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.

WHiTE Four trial results!

OCTRU

The WHiTE Four trial has now published its results in The Bone & Joint journal.

FUTURE GB Trial opens to recruitment!

OCTRU

The FUTURE GB Trial has received OCTRU Green Light approval and is now open to recruitment!

ARCADIAN trial opens to recruitment!

OCTRU

The ARCADIAN trial has received OCTRU Green Light approval and has now begun to open sites to recruitment!

HOPE-e study resumes recruitment of women with painful osteoarthritis in the hand

Main OCTRU

Researchers in Oxford are looking to recruit women who have painful osteoarthritis in joints of their hands, after resuming a study that was paused due to the COVID crisis.